NOS1 and neoplasm: Moreover, l-NMMA is currently being evaluated in a phase I trial in combination with pembrolizumab (α-PD-1) in patients with different solid tumors (NCT03236935), which may yield further clarification on the effects of NOS inhibition on the anti-tumor immune response.